CVS Health (CVS)
(Delayed Data from NYSE)
$58.42 USD
+0.59 (1.02%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $58.41 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Price, Consensus and EPS Surprise
CVS 58.42 +0.59(1.02%)
Will CVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVS
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
CVS Health (CVS) Rises Higher Than Market: Key Facts
CVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
CVS Stock Gains From Its Birth Control Prescribing Service Launch
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
Why Is CVS Health (CVS) Up 0.4% Since Last Earnings Report?
Other News for CVS
BlackRock Equity Dividend VI Fund Q2 2024 Commentary
CVS unit Oak Street Health in $60M settlement over kickback scheme
Oak Street Health to pay $60M to resolve alleged False Claims Act violations
Tommy Tuberville sells Apple, UPS, CVS, Medtronic in new disclosure
BlackRock Equity Dividend Fund Q2 2024 Commentary